Crinetics' PALSONIFY Wins EU Approval for Acromegaly, Paving Way for European Launch
CRNX sits 54% above its 52-week low of $25.83.
Summary
Crinetics Pharmaceuticals has received European Commission approval for PALSONIFY (paltusotine) for the treatment of acromegaly in adults. This marks a significant milestone as it is the company's first regulatory approval outside the U.S., following its prior FDA approval and U.S. commercial launch, and the positive EU regulatory opinion noted in the recent 10-K. The approval, which covers all 27 EU member states and three European Economic Area countries, significantly expands the total addressable market for PALSONIFY, a key product for Crinetics. Initial commercialization efforts are planned for Germany and Austria. This positive development is expected to be a material driver of future revenue growth and solidifies PALSONIFY's position as a leading therapy for acromegaly globally. Investors will now watch for details on the European launch timelines and sales ramp-up.
At the time of this announcement, CRNX was trading at $39.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4B. The 52-week trading range was $25.83 to $57.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.